Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Amy Jackson-Fisher"'
Autor:
Sripad Ram, Pamela Vizcarra, Pamela Whalen, Shibing Deng, C L Painter, Amy Jackson-Fisher, Steven Pirie-Shepherd, Xiaoling Xia, Eric L Powell
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0245638 (2021)
Immunohistochemistry (IHC) assays play a central role in evaluating biomarker expression in tissue sections for diagnostic and research applications. Manual scoring of IHC images, which is the current standard of practice, is known to have several sh
Externí odkaz:
https://doaj.org/article/b8922c40f36d48b9a4bdddcab8658a90
Autor:
Cathy C Zhang, Zhengming Yan, Bernadette Pascual, Amy Jackson-Fisher, Donghui Stephen Huang, Qing Zong, Mark Elliott, Conglin Fan, Nanni Huser, Joseph Lee, Matthew Sung, Puja Sapra
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 1, Pp 1-11 (2018)
Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early clinical studies, recent reports detailing a modified dosing regimen of GO ca
Externí odkaz:
https://doaj.org/article/2898acde00d048cd84c53471b28d4128
Autor:
Douglas D Fang, Cathy C Zhang, Yin Gu, Jitesh P Jani, Joan Cao, Konstantinos Tsaparikos, Jing Yuan, Melissa Thiel, Amy Jackson-Fisher, Qing Zong, Patrick B Lappin, Tomoko Hayashi, Richard B Schwab, Anthony Wong, Annette John-Baptiste, Shubha Bagrodia, Geritt Los, Steve Bender, James Christensen, Todd Vanarsdale
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67258 (2013)
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in both preclinical and clinical settin
Externí odkaz:
https://doaj.org/article/0c8a0a7f5f184b83815b854e748c76ff
Publikováno v:
Cancer Biology & Therapy
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Recently approved therapies have contributed to a significant progress in the management of ovarian cancer; yet, more options are needed to further improve outcomes in patients with advanced disease. Here we review the rationale and ongoing clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::720dcce23f6d249c0e4a346369db43d4
http://europepmc.org/articles/PMC7928025
http://europepmc.org/articles/PMC7928025
Autor:
Pamela Vizcarra, Eric L. Powell, Cory L. Painter, Pamela Whalen, Amy Jackson-Fisher, Shibing Deng, Steven Pirie-Shepherd, Sripad Ram, Xiaoling Xia
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 9, p e0245638 (2021)
PLoS ONE, Vol 16, Iss 9, p e0245638 (2021)
Immunohistochemistry (IHC) assays play a central role in evaluating biomarker expression in tissue sections for diagnostic and research applications. Manual scoring of IHC images, which is the current standard of practice, is known to have several sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0737889c298e5bf19f891ae9dbe279df
https://pubmed.ncbi.nlm.nih.gov/34570796
https://pubmed.ncbi.nlm.nih.gov/34570796
Autor:
Dawei Xuan, Valentina Boni, Xiaohua Xin, Shilpa Alekar, Anthony W. Tolcher, Jasgit C. Sachdev, Nehal Lakhani, Victor Moreno, Ruifeng Li, Amy Jackson-Fisher, Erica Stringer-Reasor, Michael L. Maitland, Allison R Moreau, Shivaani Kummar, Michelle Bowers, Emiliano Calvo, Eric L. Powell, Manish R. Sharma
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(16)
Purpose: We investigated safety, tolerability, pharmacokinetics, and antitumor activity of the protein tyrosine kinase 7 (PTK7)-targeted, auristatin-based antibody–drug conjugate (ADC) PF-06647020/cofetuzumab pelidotin (NCT02222922). Patients and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e4848c833b7ebf11a4a1920ed8a1bd
https://pubmed.ncbi.nlm.nih.gov/34083232
https://pubmed.ncbi.nlm.nih.gov/34083232
Autor:
Puja Sapra, Bernadette Pascual, Joseph K. T. Lee, Zhengming Yan, Qing Zong, Matthew Sung, Conglin Fan, Cathy Zhang, Nanni Huser, Elliott Mark Leonard, Amy Jackson-Fisher, Donghui Stephen Huang
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 1, Pp 1-11 (2018)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-drug conjugate for the treatment of acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early clinical studies, recent reports detailing a modified dosing regimen of GO ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60a4ca3290fb723db0d6ccf036cbbbe
http://www.sciencedirect.com/science/article/pii/S1476558617304190
http://www.sciencedirect.com/science/article/pii/S1476558617304190
Autor:
Marlena Walls, Tod Smeal, Suvi T. M. Orr, Zhengyu Liu, Cheng Hengmiao, Shuiwang Wang, Kephart Susan Elizabeth, Jean Joo Matthews, Rose Ann Ferre, Neal W. Sach, Scott L. Weinrich, Doug Behenna, Sherry Niessen, Sangita M. Baxi, Deepak Dalvie, Sujin Cho-Schultz, Dac M. Dinh, Kevin Ryan, Jim Solowiej, Elaine E. Tseng, Simon Paul Planken, Sajiv Krishnan Nair, Brion W. Murray, Jun Li Feng, Jennifer Lafontaine, Pairish Mason Alan, Shijian Ren, Michelle Hemkens, Shuibo Xin, Mehran Jalaie, Tran Khanh Tuan, Robert Steven Kania, Sutton Scott Channing, William F. Vernier, Kevin K.-C. Liu, Amy Jackson-Fisher, Beth Lunney, Min-Jean Yin, Ketan S. Gajiwala, Asako Nagata, Haiwei Xu, Michael Zientek, Ru Zhou, Daniel Tyler Richter, Simon Bailey, Martin Paul Edwards, Martha A. Ornelas, Chau Almaden, John Charles Kath, Hong Shen, Theodore O. Johnson
Publikováno v:
Journal of Medicinal Chemistry. 59:2005-2024
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often driven by a second-site mutation in the EGFR kinas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd650965ee5ecc3e2b378a7f2542e1b
https://doi.org/10.1021/acs.jmedchem.5b01633
https://doi.org/10.1021/acs.jmedchem.5b01633
Autor:
Xie Tao, Hui Wang, David Shields, Keith A. Ching, Stephanie T. Shi, Maruja E. Lira, Amy Jackson-Fisher, Xianxian Zheng, Pamela Vizcarra, Zhengyan Kan, Mark Ozeck, Gabriel Troche, Julio Fernandez, Konstantinos Tsaparikos, Xiaorong Li, Edward Rosfjord, Shibing Deng, Eric Upeslacis, Paul A. Rejto, James S. Hardwick, Judy Lucas, Ying Ding, Patrick Lappin, John Chionis
Publikováno v:
Cancer Research. 75:A2-33
Patient-Derived Xenograft (PDX) provides important preclinical model for pharmacological testing of oncology drug candidates. Molecular profiling of PDX tumors contributes to many areas of drug discovery from target discovery to development of clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f1a001b5d46f86c52437eed12b04a6e
https://doi.org/10.1158/1538-7445.transcagen-a2-33
https://doi.org/10.1158/1538-7445.transcagen-a2-33
Autor:
Eric L. Powell, Pamela Vizcarra, Roberto Gianani, Xiaohua Xin, Pamela Whalen, Stephen McComish, Amy Jackson-Fisher, Shibing Deng, Navi Mehra
Publikováno v:
Cancer Research. 79:4035-4035
Background: PF-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing Phase I clinical trial in pts with advanced solid tumors. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::504be9efd7904b6e3e12b2c090e4f42b
https://doi.org/10.1158/1538-7445.am2019-4035
https://doi.org/10.1158/1538-7445.am2019-4035